中国成人IgA肾病伴肾病范围蛋白尿患者循环抗肾病蛋白抗体研究
该单中心回顾性研究纳入234例活检证实的IgA肾病伴肾病范围蛋白尿成人患者,检测血浆抗肾病蛋白IgG和IgM。总体血清阳性率8%,合并微小病变者达35%;血清阳性者蛋白尿更重、白蛋白更低、慢性病变更轻,激素治疗完全缓解率更高(67% vs 30%),复合肾脏终点更少(0% vs 28%)。
要点
- IgA肾病伴肾病范围蛋白尿患者抗肾病蛋白抗体阳性率8%,合并微小病变者达35%。
- 血清阳性者表现为足细胞病样表型:蛋白尿更重、白蛋白更低、慢性病变更轻。
- 血清阳性者激素治疗完全缓解率更高(67% vs 30%),复合肾脏终点更少(0% vs 28%)。
核心结论
- 循环抗肾病蛋白抗体标记IgA肾病合并微小病变的足细胞病样表型,并在无明确足细胞病的IgA肾病患者中定义独特的肾病综合征表型。
- 靶向血清学检测可能有助于亚组识别和指导个体化管理。
研究设计与样本
- 单中心回顾性研究,纳入2003至2020年234例活检证实的IgA肾病伴肾病范围蛋白尿(≥3.5 g/d)成人患者。
- 采用酶联免疫吸附试验检测血浆抗肾病蛋白IgG和IgM,预设亚组包括肾病综合征(n=105)和合并微小病变(n=17),以微小病变和局灶节段性肾小球硬化队列为参照。
主要发现
- 总体抗肾病蛋白血清阳性率8%(IgG 6%,IgM 2%);合并微小病变者阳性率35%,无微小病变者6%。
- 肾病综合征患者血清阳性率14%;合并微小病变者35%,无微小病变者10%。
- 血清阳性者蛋白尿中位数8.1 vs 4.9 g/d,血清白蛋白21.9±6.5 vs 31.0±7.2 g/l,尿红细胞更少,eGFR相似。
- 血清阳性者活检慢性病变更轻(更多M0/S0/T0),更常接受糖皮质激素治疗。
- 血清阳性者完全缓解率更高(总体67% vs 30%;肾病综合征内80% vs 43%),复合肾脏终点更少(0% vs 28%)。
临床怎么用
- 对IgA肾病伴肾病范围蛋白尿患者可考虑检测抗肾病蛋白抗体,以识别足细胞病样表型和可能对激素反应更好的亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Antinephrin autoantibodies are detectable in podocytopathies such as minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS); however, their prevalence and clinical relevance in IgA nephropathy (IgAN) with nephrotic-range proteinuria (NRP) and nephrotic syndrome (NS) are unclear. METHODS: This single-center retrospective study enrolled 234 adults with biopsy-proven IgAN and NRP (≥ 3.5 g/d) from 2003 to 2020. Plasma antinephrin IgG and IgM were measured using enzyme-linked immunosorbent assay. Prespecified subgroups included NS (n = 105) and concurrent MCD (n = 17). Clinicopathologic features, treatment, and outcomes were compared by serostatus, with MCD and FSGS cohorts as references. RESULTS: Overall antinephrin seropositivity was 8% (IgG: 6%, IgM: 2%). The seropositivity rate was 35% in patients with MCD versus 6% in those without. In patients with NS, seropositivity was 14%; rates were 35% with and 10% without MCD. Seropositive patients had heavier proteinuria (median: 8.1 vs. 4.9 g/d), lower serum albumin (21.9 ± 6.5 vs. 31.0 ± 7.2 g/l), fewer urinary red blood cells (RBCs), and similar estimated glomerular filtration rate (eGFR). Their biopsies showed milder chronic lesions (more M0/S0/T0). Seropositive patients more often received glucocorticoids and achieved higher complete remission (CR) rates (67% vs. 30% overall; 80% vs. 43% within NS) and fewer composite renal endpoints (0% vs. 28%). Multivariable analysis showed that antinephrin positivity was associated with a trend toward higher CR rates. CONCLUSION: Circulating antinephrin antibodies mark a podocytopathy-like phenotype in IgAN with MCD (MCD-IgAN) and define a distinct NS phenotype in patients with IgAN without overt podocytopathy. Targeted serologic testing could facilitate subgroup identification and guide tailored management.
引用
- Si F, Shu Y, Tang C, et al. Circulating Antinephrin Antibodies in Adult Chinese Patients With IgAN and Nephrotic-Range Proteinuria. Kidney Int Rep. 2026. PMID: 42404869. doi:10.1016/j.ekir.2026.106640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。